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Abstract
When faced with the management of the patient on intensive care
with acute kidney injury, the clinician has various choices to
consider. The conventional therapy, where appropriate, is renal
replacement therapy. This technique used to be relatively
straightforward but now a relative feast of alternatives is available,
not least in choice of buffer and anticoagulant. Two recent studies
add to the growing body of literature concerning alternative
anticoagulant regimes, and one in particular should lead to a
change in practice for many of us. We also review some new
studies on biomarkers in the diagnosis of acute kidney injury as
well as add yet another nail in the coffin for loop diuretics in the
therapy of acute kidney injury.
‘Where observation is concerned, 
chance favours only the prepared mind’
(Louis Pasteur, 1822–1895)
A renal flavour this month, for which we make no apologies!
As we all know, acute renal failure is no more: we now deal in
acute kidney injury (AKI)! We are still plagued by the lack of a
useful early indicator for kidney injury, however, and the
search for this holy grail continues.
This prize may be getting closer, as a report by Haase-Fielitz
and colleagues in Critical Care Medicine examines the role of
serum biomarkers in predicting AKI in a cohort of patients
following cardiac surgery [1]. They employed neutrophil
gelatinase-associated lipocalin (a marker of tubular cell injury)
and cystatin C (a marker of glomerular filtration rate)
measured in serum together with conventional markers of
renal function. The end points were development of AKI
(defined as an increase in serum creatinine >50%), the need
for renal replacement therapy and hospital mortality. This
study demonstrated that the novel biomarkers predicted AKI
approximately 48 hours before conventional measures, such
as creatinine. In particular, biomarker levels 24 hours post-
operatively proved particularly useful. The study has some
limitations, as the authors point out, but it is the largest adult
study reported thus far.
Where does Haase-Fielitz and colleagues’ study leave us?
Clearly this field will continue to expand and no doubt many
more papers will be produced on the role of novel
biomarkers, but how will it change our practice? One hopes
that early identification of patients that have undergone renal
injury (in whatever guise) will lead to improved outcomes
through augmented observations and avoidance of further
renal insult. The acid test will be to demonstrate that early
intervention improves outcome in these patients. Then the
holy grail may well have been found.
Following on from this, a novel report from Heemskerk and
colleagues examines the role of an infusion of alkaline phos-
phatase on renal function in patients with sepsis [2]. The
rationale behind this study is that exogenous infusion of
alkaline phosphatase appears to decrease inducible nitric
oxide synthase activity, reduce nitric oxide metabolite produc-
tion and perhaps maintain the integrity of the proximal tubule
during severe sepsis. This is a small study and therefore no
conclusions can be drawn regarding benefits in terms of
mortality or morbidity; however, the study does demonstrate
some novel findings. Induction of inducible nitric oxide
synthase and renal nitric oxide metabolite production was
reduced, as was the excretion of markers of proximal tubule
damage. Whether such findings will eventually lead to a
change in the management of such patients, only time will tell.
Unlike such new approaches, the use of loop diuretics in AKI
has been applied in almost all scenarios despite a lack of any
evidence that they result in any benefit in real terms – such as
mortality or, indeed, renal recovery. It appears that the theo-
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retical benefits coupled with the reassurance of increased
urine flow outweigh the lack of data demonstrating a benefit.
Van der Voort and colleagues have further examined the use
of furosemide in a randomised, double-blind, placebo-
controlled study of intensive care unit patients after the use of
haemofiltration [3]. The results are unsurprising. Those
patients treated with loop diuretics had an increased urine
output and sodium excretion. There was no benefit observed
on renal recovery or on creatinine clearance. If anything, the
placebo group fared better in terms of renal recovery –
although the treated group did have a higher Sequential
Organ Failure Assessment score and were older. For those
diuretic zealots among you, this paper offers little solace.
After AKI has been diagnosed by whatever means, and all
therapeutic options have been tried, we turn to our extra-
corporeal systems for help. The recent literature has
demonstrated a great deal of interest as regards the choice
of anticoagulant employed, and in particular the use of
regional anticoagulation in order to address the loss of
treatment time, additional costs and not least the nursing time
associated with premature circuit loss.
A novel approach to this issue is described in intensive care
medicine [4]. A cooling device was applied to a continuous
venovenous hemofiltration circuit in order to cool the blood to
20ºC, coupled with a warming device post filtration that
ensured the returning blood was heated to 38ºC. Twelve
healthy pigs were selected as subjects and were exposed to
6 hours of either continuous venovenous hemofiltration with
cooling or normothermia. Other factors, such as fluid balance,
were identical. An array of parameters was measured but the
main finding was that where cooling was not applied five out
of six circuits clotted prematurely. None of the cooled circuits
clotted prematurely. Clearly much more work has to be done –
not least on the safety aspects of blood undergoing such
regular cycles of rewarming, but also the period of study
(6 hours) is much shorter than that applied clinically and also
these were healthy animals not a patient in multiorgan failure.
Will such technology be coming to your intensive care unit in
the near future? Probably not; however, if you are not a fan of
regional anticoagulation, then the excellent study by Oude-
mans-van Straaten and colleagues should make you sit up
and take notice [5].
This study on 200 patients receiving continuous venovenous
hemofiltration randomised patients to systemic anticoagu-
lation with nadroparin or regional citrate anticoagulation [5]:
the largest such trial to date. Citrate inhibits coagulation
through ionised Ca2+ chelation, with the calcium citrate
complex being in part filtered or metabolised. The primary end
points of this study were safety and efficacy powered on
adverse events necessitating discontinuation of therapy as
well as transfusion requirements, circuit survival and
metabolic and clinical outcomes. Interestingly, there was a
significant increase in the number of adverse events seen in
the nadroparin-treated group, little difference in transfusion
requirements and no differences in circuit survival. So it
appears that citrate is safer.
As Pasteur commented, however, chance favours only the
prepared mind. The stunning result of Oudemans-van
Straaten and colleagues’ study is the significant and wholly
unexpected survival benefit conferred by the use of regional
citrate anticoagulation. Among the studied patients, the
3-month mortality was a staggering 17% lower in the regional
citrate anticoagulation-treated group and post hoc analysis
demonstrated that the observed survival benefit was most
marked in patients with sepsis, severe multiorgan failure and
after surgery [5]. Such a survival benefit cannot be ignored
and, although some may point to this being a single-centre
study and that fractionated heparins were used, the beauty of
this study is that daily practice was not changed for the study
purposes and that the survival benefit was seen throughout
the study period. Single-centre studies do play an important
role with regards to intensive care unit practice as we are not
blessed with the huge, homogeneous numbers recruited to
cardiology studies, for example. This work is already being
applied to a multicentre study, which no doubt will be further
replicated. This should lead to much more study into the
basic mechanisms behind the observations, which may
benefit all our patients. The question one must now ask
oneself is not should I be thinking of using regional citrate
anticoagulation, but when should I start? The emergence of
commercially available systems can only accelerate this
process.
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